Biocept Appoints Financial Executive Quyen Dao-Haddock to its Board of Directors
November 18 2022 - 8:00AM
Business Wire
Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular
diagnostic assays, products and services, announces the appointment
of Quyen Dao-Haddock to its Board of Directors, effective
immediately, increasing Board membership to eight. Ms. Dao-Haddock
is a certified public accountant (CPA) with more than 20 years of
financial and accounting experience. She will serve on Biocept’s
Audit Committee.
“Quyen’s extensive financial experience leading accounting and
finance departments, and overseeing technical accounting, budgeting
and forecasting, financial modeling, cash management and SEC
reporting, make her a valuable addition to our Board and its Audit
Committee,” said Samuel D. Riccitelli, Biocept’s Chairman, and
interim President and CEO. “We expect Quyen will make significant
contributions as we seek standard-of-care status for our
proprietary cerebrospinal fluid assay CNSide™ and focus on
delivering value to our stockholders.”
“It’s an exciting time to join the Biocept Board as the Company
directs its resources toward providing valuable information to
improve clinical outcomes for patients with cancer and central
nervous system involvement, who oftentimes have extremely poor
prognoses,” said Ms. Dao-Haddock. “I’m delighted to utilize my
skills and expertise to support the advancement of CNSide and the
Company’s diagnostic programs.”
Ms. Dao-Haddock serves as controller of IQHQ, Inc., a $2.5
billion start-up real estate investment trust (REIT) focused on the
life sciences industry, with responsibility for scaling the
accounting and finance department and establishing and implementing
comprehensive accounting policies. She previously was Chief
Accounting Officer of Presidio Property Trust, Inc., where she was
responsible for all financial and accounting operations of this
REIT with more than $30 million in annual revenues and $200 million
in assets. Earlier she was Corporate Controller of American Assets
Trust, Inc., an NYSE-listed REIT with more than $315 million in
annual revenues and $2 billion in assets, and Controller at Pacific
Corporate Group, LLC, a private equity firm with $30 million in
revenue and $16 billion in assets. She began her career as an Audit
Manager at KPMG LLP.
Ms. Dao-Haddock serves on the Audit & Compliance Committee
of Sharp HealthCare. She received a BS in Business Administration,
Accounting from San Diego State University.
About Biocept
Biocept, Inc. develops and commercializes molecular diagnostic
assays that provide physicians with clinically actionable
information for treating and monitoring patients diagnosed with a
variety of cancers. For more information, visit www.biocept.com.
Follow Biocept on Facebook, LinkedIn, Twitter, and Instagram.
Forward-Looking Statements Disclaimer
This press release contains forward-looking statements that are
based upon current expectations or beliefs, as well as a number of
assumptions about future events. Although we believe that the
expectations reflected in the forward-looking statements and the
assumptions upon which they are based are reasonable, we can give
no assurance that such expectations and assumptions will prove to
be correct. Forward-looking statements are generally identifiable
by the use of words like "may," "will," "should," "could,"
"expect," "anticipate," "estimate," "believe," "intend," “goal,” or
"project," or the negative of these words or other variations on
these words or comparable terminology. To the extent that
statements in this press release are not strictly historical,
including, without limitation, statements regarding our ability to
establish CNSide as the new standard-of-care diagnostic test for
patients with metastatic cancer that has spread to the central
nervous systems, and the ability of our products, including CNSide,
to provide physicians with clinically actionable information for
treating and monitoring patients diagnosed with a variety of
cancers, such statements are forward-looking, and are made pursuant
to the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. The reader is cautioned not to put undue
reliance on these forward-looking statements, as these statements
are subject to numerous risks and uncertainties, including risks
and uncertainties associated with the ability of our products to
compete successfully with competitive products or treatments; our
ability to obtain and maintain adequate reimbursement for our
products; and the risk that our products and services may not
perform as expected. These and other factors are described in
greater detail under the "Risk Factors" heading of Biocept’s
Quarterly Report on Form 10-Q for the quarter ended June 30, 2022,
filed with the SEC on November 10, 2022. The effects of such risks
and uncertainties could cause actual results to differ materially
from the forward-looking statements contained in this press
release. We do not plan to update any such forward-looking
statements and expressly disclaim any duty to update the
information contained in this press release except as required by
law. Readers are advised to review our filings with the SEC at
http://www.sec.gov/.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221118005082/en/
Investor and Media Contact: Jody Cain, LHA Investor
Relations Jcain@lhai.com, 310-691-7100
Biocept (NASDAQ:BIOC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Biocept (NASDAQ:BIOC)
Historical Stock Chart
From Apr 2023 to Apr 2024